Dr Reddy's Laboratories Ltd 500124
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Haleon to Sell Nicotine-Quitting Aid Business for $634 Million — Update
-
Haleon to Sell Nicotine-Quitting Aid Business for $634 Million
-
Dr. Reddy's Laboratories on Track for Largest Percent Increase Since May 2022 — Data Talk
-
Nestle India Reports Rise in Quarterly Profit, Announces JV With Dr. Reddy's Laboratories
-
Dr. Reddy's Laboratories on Pace for Largest Percent Increase Since May 2022 — Data Talk
-
Indian Dr. Reddy's in Talks to Buy Haleon's Nicotinell, Sky News Reports
-
Coya Therapeutics Strikes Development, Commercialization Deal With Dr. Reddy's for ALS Drug
Trading Information
- Previous Close Price
- ₹6,757.90
- Day Range
- ₹6,676.95–6,779.95
- 52-Week Range
- ₹5,212.10–7,101.00
- Bid/Ask
- ₹6,891.15 / ₹6,612.05
- Market Cap
- ₹1.12 Tril
- Volume/Avg
- 6,259 / 22,137
Key Statistics
- Price/Earnings (Normalized)
- 21.28
- Price/Sales
- 3.90
- Dividend Yield (Trailing)
- 0.59%
- Dividend Yield (Forward)
- 0.59%
- Total Yield
- 0.59%
Company Profile
Dr. Reddy’s is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy’s also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy’s has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy’s also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Large Core
- Total Number of Employees
- 27,048
- Website
- https://www.drreddys.com
Competitors
Valuation
|
Metric
|
500124
|
NVS
|
VTRS
|
|---|---|---|---|
Price/Earnings (Normalized) | 21.28 | 16.26 | 4.15 |
Price/Book Value | 3.83 | 5.55 | 0.70 |
Price/Sales | 3.90 | 4.83 | 0.90 |
Price/Cash Flow | 17.21 | 14.81 | 4.32 |
Price/Earnings
500124
NVS
VTRS
Financial Strength
|
Metric
|
500124
|
NVS
|
VTRS
|
|---|---|---|---|
Quick Ratio | 1.66 | 0.61 | 0.65 |
Current Ratio | 2.55 | 0.93 | 1.53 |
Interest Coverage | — | 12.34 | −0.13 |
Quick Ratio
500124
NVS
VTRS
Profitability
|
Metric
|
500124
|
NVS
|
VTRS
|
|---|---|---|---|
Return on Assets (Normalized) | 14.72% | 13.97% | 7.02% |
Return on Equity (Normalized) | 20.51% | 33.01% | 16.41% |
Return on Invested Capital (Normalized) | 18.64% | 20.66% | 9.80% |
Return on Assets
500124
NVS
VTRS
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Zoetis Inc Class A
ZTS
| Xckbfvxnrf | Xwgz | $87.2 Bil | |||
| Merck KGaA ADR
MKKGY
| Xxwywpjjm | Ybrjv | $75.7 Bil | |||
| Haleon PLC ADR
HLN
| Rzgvmrfr | Rlp | $48.2 Bil | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| Lsmzlbr | Hmmk | $20.0 Bil | |||
| Viatris Inc
VTRS
| Jdpdplgs | Crvss | $13.7 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Qbbmdmnp | Jrhx | $13.4 Bil | |||
| Catalent Inc
CTLT
| Fthxyvp | Gvwdc | $11.0 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Qvxrqtbby | Vzcrfk | $3.5 Bil | |||
| Perrigo Co PLC
PRGO
| Bdqkjqmj | Mwrqz | $3.4 Bil | |||
| Green Thumb Industries Inc
GTBIF
| Szblvlzrrb | Msll | $2.4 Bil |
United States